Last updated on April 17, 2014 at 1:21 EDT

Elsevier’s MEDalternatives Offers Additional Cost Saving Options for Payers and Members

February 6, 2013

TAMPA, Florida, February 6, 2013 /PRNewswire/ –

New comprehensive resource for drug therapy options and costs helps health
plan payers and members save on drug spend with information on alternative therapies

Elsevier’s Gold Standard [http://www.goldstandard.com ], a leading drug information
provider, today announced the launch of the MEDalternatives
[http://www.goldstandard.com/product/drug-reference-patient-education/medalternatives ](TM)
database, a comprehensive resource for drug therapy options designed to give health plans
and their members additional drug cost savings options through access to information on
alternative therapies. MEDalternatives uses only evidence-based alternatives that have
comparable or better efficacy and safety, compared to current prescriptions.

MEDalternatives covers a broad range of health conditions and the widest scope of
medications, including a complete offering of drugs, drug classes, and product
formulations. It returns alternatives within the class of the patient’s current medication
and across classes, including both generics and brands, and also provides therapeutically
appropriate choices among subclasses of drugs.

MEDalternatives includes complete dosing options to ensure accurate comparisons in
daily/weekly regimens and monthly/yearly costs, including those for in-store purchase
versus mail-order delivery.

“MEDalternatives delivers a unique payer solution that identifies safe and cost-
effective medication alternatives for achieving therapy compliance and prescription cost
savings,” said Marianne Messer, President, Elsevier’s Gold Standard. “This will help our
payer and PBM clients reduce prescription drug costs, particularly those who have already
maximized their brand-to-generic switching, and improve medication adherence.”

MEDalternatives helps:

        - Simplify drug regimens and drive down costs for payers and patients
        - Improve compliance for healthier and less expensive outcomes
        - Payers control prescription costs by offering therapeutic alternatives on
          brand-to-brand drugs, as well as brand-to-generic drugs
        - Payers educate providers and members on where savings can be attained on drugs
        - PBMs (Pharmacy Benefit Managers) enforce formulary compliance
        - Help providers identify alternative therapies to reduce costs
        - Guide consumers toward more affordable, safer and more effective medication
        - Involve consumers in these choices, knowing that cost and convenience play a
          central role in adherence to treatment
        - Prepare consumers to discuss options with their healthcare providers
        - Boost patients' satisfaction with their drug benefits

MEDalternatives is derived from the most technologically sophisticated drug database
available today and will easily integrate within and across diverse healthcare systems.

For more information about Elsevier’s Gold Standard and MEDalternatives, visit


Elsevier’s Gold Standard

Based in Tampa, FL, Elsevier’s Gold Standard uses innovative technologies to provide a
complete suite of drug information and decision support solutions. With a tenacious
commitment to product quality, Elsevier’s Gold Standard solutions empower healthcare
organizations, professionals and consumers to meet the most pressing healthcare
challenges, improve patient safety and ensure optimal outcomes. To learn more about
Elsevier’s Gold Standard, visit http://www.goldstandard.com.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], ClinicalKey
[http://www.clinicalkey.com ] and Mosby’s Nursing Suite [http://www.confidenceconnected.com
], which enhance the productivity of science and health professionals, and the SciVal
suite [http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which
help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading provider of professional information
solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

        Media contact
        Christopher Capot
        Director, Corporate Relations

SOURCE Elsevier

Source: PR Newswire